Compare Recursion Pharmaceuticals Inc (RXRX) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Sezzle Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B), while Sezzle Inc trades at $128.64 (market cap $3.95B). The key difference: Sezzle Inc is the larger of the two by market cap, and Sezzle Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 23 Days and Sezzle Inc for 15 Days on average.
| RXRX | SEZL | |
|---|---|---|
Market Cap | $2.14B | $3.95B |
Volume | 30,789,535 | 550,075 |
Sector | Health | Financials |
52-Week High | $6.79 | $188.55 |
52-Week Low | $2.84 | $50.97 |
Typical Hold Time | 23 Days | 15 Days |
Enterprise Value | $1.66B | $3.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
SEZL trades at $117.22, up 2.96% today, showing strong momentum with bullish technical indicators and trading above key support levels. The company demonstrates exceptional financial performance with 51.7% revenue growth in Q2 2026, 30.35% net income margin, and 88.85% ROE. Recent product launches including Sezzle Send and SezzleCash are driving user acquisition and platform growth.
SEZL presents a compelling growth opportunity with analyst consensus price target of $168 representing 43% upside potential. Key risks include competitive BNPL market pressures and potential credit quality concerns. The stock's premium valuation (P/E 25.71) is supported by strong earnings growth and profitability metrics, though investors should monitor execution of expansion initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
